Happy Holidays! The prIME LINES team would like to extend a sincere thank you for a wonderful 2019. We look forward to a successful 2020 with you, our valued readers. We’ll see you again January 6th, 2019, with the latest news and information. Thank you for your continued interest in our blog.
At the 2019 San Antonio Breast Cancer Symposium (SABCS), Rashmi Murthy, MD (University of Texas MD Anderson Cancer Center, Houston, United States), presented results from the randomized phase III HER2CLIMB trial, which evaluated the addition of the HER2-targeting tyrosine kinase inhibitor (TKI) tucatinib to trastuzumab and capecitabine in 612 patients with progressive metastatic HER2-positive breast […]
Triple-negative breast cancer (TNBC) is difficult to treat due to the lack of targetable receptors, and patients often have poor outcomes due to the lack of effective treatment options. At the 2019 San Antonio Breast Cancer Symposium (SABCS), Marion van Mackelenbergh, MD (University of Kiel, Germany), presented results from a subgroup of patients with early-stage […]
Children as well as adolescent and young adult (AYA) patients with acute lymphoblastic leukemia (ALL) who relapse following frontline therapy typically receive intensive chemotherapy followed by hematopoietic stem cell transplant (HSCT). Unfortunately, this treatment option is not always effective, and these patients tend to have poor outcomes. At the 2019 American Society of Hematology (ASH) […]
At the 2019 American Society for Hematology (ASH) Annual Meeting, Saad Usmani, MD, MBBS (Atrium Health, Charlotte, North Carolina, United States), presented results from the randomized phase III CANDOR trial, evaluating the combination of carfilzomib, dexamethasone, and daratumumab (KdD) for treatment of patients with relapsed/refractory multiple myeloma (Abstract LBA6). Patients (N = 466) who had […]
Opioid misuse is a major public health concern. Because many patients with cancer rely on pain medication to manage cancer symptoms, there is a risk for opioid dependence in this population. To clarify the risk of opioid dependence among patients with cancer, a recent study evaluated common factors associated with opioid misuse among 106,732 cancer […]
Diagnosis of cancer in early stages of disease allows for a wider range of effective treatment options and a greater chance for cure. Fortunately, a new study shows that more cancer diagnoses are occurring at early stages, likely due to an increased awareness of cancer symptoms and greater availability of screening programs. The study, published […]